CAM HSBIOTECH-U

CSPC PHARMA FY2026 Q1 Earnings Release on May 27 Pre-Market (BJT), Forecast Revenue HKD 7.905 B, EPS HKD 0.102

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

CSPC's SYH2095 receives clinical trial approval and FDA clearance, trials set to begin in April 2026

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

China Biopharma spends 10 million HKD to repurchase 1.89 million shares on May 18

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

China Biopharma spends 10.0269 million HKD to repurchase 1.87 million shares

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Zhongtai Securities lowers Sanhome's earnings forecast and maintains Buy rating

BeiGene's Brukinsa Approved by FDA

China Biopharmaceutical Announces Preclinical Results of Obesity Treatment Candidate TQF6422

Hanson Pharma Group Begins HS-10541 Clinical Trial with NMPA Approval

China Bio-Pharmaceuticals repurchased 1.78 million shares

Innovent Biologics to Present Phase 3 Trial Results of Mazdutide at 2026 ADA Scientific Sessions

CStone Pharmaceuticals Reaps Significant Benefits from 707 Authorization Deal with Pfizer

BGI Q1 Profit Surges, Revenue Breaks 10 Billion Yuan

Jade Pharmaceutical's SYS6010 Enters Phase 3 Clinical Trials for Esophageal Squamous Cell Carcinoma

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

STECH

516500

03174

03069

159992

09069

The China Securities Regulatory Commission released a quarterly report, indicating that Hong Kong's total IPO fundraising exceeded HKD 280 billion last year, ranking first in the world. Since the launch of the special line for technology companies in May last year, 119 applications from unprofitable biotechnology and specialized technology companies have been received. Last year, the average daily trading volume of the Hong Kong Stock Connect increased by 151%, with a cumulative net inflow of over HKD 5.1 trillion. In terms of digital assets, the managed assets of tokenized retail money market funds grew to HKD 8.66 billion, and the total market value of ETFs increased to HKD 618.7 billion. The net inflow of registered funds in Hong Kong grew by 118.5%

AASTOCKS

Hang Seng TECH Index

ChinaAMC CSI Biotechnology Theme ETF

First Trust NYSE Arca Biotech Index Fd

ICBCCS SSE STAR Biology and Medicine ETF

Huatai-PB CSOP Hang Seng Technology ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

GX HS TECH

CSOP HEALTHCARE

E Fund Hang Seng SCHK Innovative Drug ETF

Huatai-PB Hang Seng Biotech ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Penghua SSE STAR Biology and Medicine ETF

CAM HSBIOTECH

CAM HS TECH-R

CAM HS TECH-U

Yinhua CSI Innovative Drugs Industry ETF

ISHARESHSTECH

China Universal CSI Biotechnology Theme Index Initiating Fund(LOF)-A

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Huaan Hang Seng Biotech ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Guotai CSI Bio-medicine ETF

China Universal Hang Seng Technology ETF(QDII)

Ping An CSI Medicine and Medical Device Innovation ETF

CAM HS TECH

Minsheng Royal CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

Tianhong CNI BIOMEDICINE ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

E Fund CSI Biotechnology Theme ETF

Bosera Hang Seng Health Care ETF(QDII)

China Southern Hang Seng Biotech ETF(QDII)

CSOP HS TECH

CSRC: The special line for science and technology enterprises received 119 applications from unprofitable biotechnology and specialized technology companies last year

The Hang Seng Index Company plans to expand its biotechnology index product ecosystem. CEO Wu Wanwen pointed out that the Hang Seng Index performed excellently last year, with an annual increase of 27.8%. In the future, it will strengthen the market leadership of the technology and biotechnology sectors and expand the scale of related asset management. The biotechnology index rose 8.8% this January, surpassing the 7.4% increase of the Hang Seng Composite Index. The company will continue to develop more derivative products to support the development of the healthcare industry

The Hang Seng Index Company plans to expand its biotechnology index product ecosystem

09820

ALPHAMAB-B (9966.HK) has seen a continuous decline after the market closed on January 20, with the overall Hong Kong biotechnology sector lacking excitement. The company has not announced any significant clinical progress or financing recently, and although trading volume slightly increased throughout the day, there was no significant action from major players, as investors' focus has shifted back to sector rotation. There are rumors in the news that the adjustment window for the medical insurance catalog is approaching, and market funds are leaning towards innovative drugs and emerging sectors, while ALPHAMAB has not shown significant movement following the hot trends. The intraday fluctuations have been mild, with no significant gathering of major players, and the buying pressure remains to be validated. On the technical side, the MACD continues to trend downward, and the 5-day moving average is providing short-term resistance, raising doubts about the sustainability of any rebound. Moving forward, attention should be paid to the substantive progress of medical insurance negotiations and the future structural rotation of the sector. If the biotechnology sector experiences another overall pullback or if the company faces unexpected negative news, short-term pressure may significantly increase. The operational suggestion is to continue observing from the right side, closely track marginal policy changes and sector movements, and wait for signals of major capital action to emerge

Technical Forecast

GX CN BIOTECH-U

Hwabao WP CSI Hong Kong Connect Medical Treatment Thematic ETF

Yinhua CSI HK Equities Medical and Health Integration ETF

GX CN BIOTECH

Ping An CSI HK Equities Medical and Health Integration ETF

E Fund CSI HK Equities Medical and Health Integration ETF

Tianhong Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drugs Selected 50 ETF

ALPHAMAB-B

Morning Trend | ALPHAMAB is testing the bottom with reduced volume, will the main opportunities in the pharmaceutical sector rotate?

CAM HSBIOTECH-U(09069.HK)

CSRC: The special line for science and technology enterprises received 119 applications from unprofitable biotechnology and specialized technology companies last year

The Hang Seng Index Company plans to expand its biotechnology index product ecosystem

Morning Trend | ALPHAMAB is testing the bottom with reduced volume, will the main opportunities in the pharmaceutical sector rotate?